611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Life in Space May Take Toll on Spinal MusclesHealth Tip: Understanding a Heart MurmurCalling All Blood Donors …Opioids Now More Deadly for Americans Than Traffic AccidentsWhy Your Heart Needs a Good Night's SleepNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseVaccines: Not Just for KidsExercise Caution to Protect Your Skin at the GymMake Cancer Prevention a Priority in 2019AHA: New Cholesterol Guidelines Put Ethnicity in the SpotlightBroad-Range Ebola Drug Shows Promise in Animal TestsPrescription Opioids May Raise Pneumonia RiskHealth Tip: Prevent Travelers' DiarrheaCancer Patients May Face Greater Risk of ShinglesThyroid Surgery Complications Can Land Some Back in the HospitalRadiation Doses From CT Scans Vary WidelyHealth Tip: Job-Related Chemical Exposure Through the SkinJob Insecurity May Take a Toll on Your HeartPhysical Therapy Can Keep Sports Injuries at BayPersistent Cough May Mean See Your Doctor1 in 10 Adults Have Food Allergies, But Twice as Many Think They DoCatching Up on News About Catch-Up SleepHepatitis C Screening Can Help Prevent Liver DiseaseCan Herbal Drug Kratom Kill?Cholesterol Levels Spike After ChristmasDeadly Meningitis B Targets College StudentsNew Cholesterol Drug's High Price May Not Be Worth It: StudyAsthma Often Goes Undetected in Urban Teens, Study FindsBe Alert for Concussions in Young AthletesHow Seniors Can Prevent Hypothermia This WinterWhopping Numbers on Whooping CoughKidney Disease Risk Tied to Sugar-Sweetened DrinksHealth Tip: Understanding Whooping CoughHealth Tip: Strep Isn't an Ordinary Sore ThroatHolidays' Pitfalls for Those With Food AllergiesWinter's Many Challenges to Eye HealthHeart Risks High in Older Cancer Patients Before DiagnosisCertain Antibiotics Tied to Deadly Heart Vessel Tears: FDAHepatitis C Cases Cluster in States Hit Hard by OpioidsEven Non-Concussion Head Hits Affect Young Football Players' VisionAverage American Getting Fatter, but Not Taller1 in 4 People Over 25 Will Be Hit by StrokeWearing Contacts 24/7 Can Bring Infection, Blindness, Doctors WarnFood Allergies Tied to MS RelapsesRunaway Immune System May Play Role in Chronic Fatigue SyndromeMigraine's 'Silver Lining': Lowered Risk for Diabetes?Health Tip: Use Medical Devices SafelyFast Facts for Men (and Women) About High CholesterolDon't Let Holiday Season Stress Worsen Your Allergies, AsthmaSave Your Skin From the Ravages of Cold Weather
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

New Drug Approved for Antibiotic-Resistant Lung Disease

HealthDay News
by -- Scott Roberts
Updated: Oct 1st 2018

MONDAY, Oct. 1, 2018 (HealthDay News) -- Arikayce has been approved by the U.S. Food and Drug Administration to treat lung disease caused by Mycobacterium avium complex (MAC) bacteria among people who don't respond to conventional therapies, the FDA said in a news release.

MAC bacteria are commonly found in water and soil. Symptoms of MAC-triggered lung disease include chronic cough, fatigue, weight loss, night sweats and possibly shortness of breath and coughing up blood, the FDA said.

"As bacteria continue to grow [resistant] to currently available antibiotics, we need to encourage the development of drugs that can treat resistant infections," said FDA Commissioner Dr. Scott Gottlieb.

Arikayce (amikacin liposome inhalation suspension) is the first medication approved under new agency rules that encourage development and approval of antibacterial and antifungal drugs to treat certain serious or life-threatening infections, the FDA said.

Arikayce is an inhaled treatment taken through a nebulizer. In clinical studies, 29 percent of those treated with the drug showed no growth of mycobacteria for three consecutive months, compared with 9 percent of trial participants who weren't treated with Arikayce, the FDA said.

The drug's label includes a boxed warning that it could trigger inflamed lungs, tightening of the respiratory airways, worsening lung disease and spitting up blood, the agency said.

Arikayce is produced by Insmed Inc. of Bridgewater, N.J.

More information

The FDA has more about this approval.